Form 4: Nuvalent Director Matthew Shair Sells Shares Under 10b5-1 Plan

Director Matthew Shair of Nuvalent, Inc. sold a portion of his Class A Common Stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew Shair, a director at Nuvalent, Inc., executed multiple sales of Class A Common Stock on November 25, 2024.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on December 21, 2023.
• The sales were executed at weighted average prices of $95.71, $96.69, and $97.4 per share.
• A total of 2,000 shares were sold directly, and the remaining shares are held indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust.
• Following these transactions, Shair directly owns 1,427,197 shares and indirectly owns 222,522 shares.

Sentiment

Score: 5

Explanation: The document is a routine filing related to insider trading under a pre-arranged plan, which is neither positive nor negative in itself.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. Rule 10b5-1 plans are often used to avoid accusations of insider trading by allowing insiders to sell shares at predetermined times.

Comparison to Industry Standards

• Sales by insiders are a normal part of the market, and the use of 10b5-1 plans is a common practice among executives and directors of publicly traded companies.
• The volume of shares sold by Matthew Shair is relatively small compared to his total holdings, which is typical for transactions under 10b5-1 plans.
• Comparable companies often see similar filings from their directors and officers.

Stakeholder Impact

• The impact on shareholders is likely to be minimal, as the transactions were conducted under a pre-arranged plan and represent a small portion of Shair's total holdings.

Key Dates

Keywords

insider trading, Form 4, Rule 10b5-1, stock sale, Matthew Shair, Nuvalent, NUVL, director